Material Event (Form 8-K)

Item 8.01. Other Events.

On August 19, 2025, Alaunos Therapeutics, Inc. (the "Company") was notified by Listing Qualifications staff of The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the continued listing requirements of the Nasdaq Capital Market.

As previously disclosed, on April 7, 2025, the Company received a notice from the Listing Qualifications staff of Nasdaq (the "Notice") stating that the Company did not comply with the continued listing requirements of the Nasdaq Capital Market under Nasdaq Listing Rules 5550(b)(1), 5550(b)(2), or 5550(b)(3), which require, respectively, a minimum of (i) $2.5 million in stockholders' equity, (ii) $35 million in market value of listed securities, or (iii) $500,000 of net income from continuing operations. In its Annual Report on Form 10-K for the year ended December 31, 2024, the Company reported stockholders' equity of $2.06 million, which did not satisfy the Rule 5550(b)(1) requirement.

The Notice had no immediate effect on the Company's listing, and the Company submitted a compliance plan within 45 calendar days, as permitted under Nasdaq rules. Based on the Company's Quarterly Report on Form 10-Q for the period ended June 30, 2025, evidencing stockholders' equity of $3.66 million, the Listing Qualifications staff of Nasdaq has determined that the Company complies with the Nasdaq Listing Rules and has confirmed the matter is now closed.